Pharmaceuticals & Biotechnology

Beam Therapeutics Inc. CEO pay

Sravan K. Emany, President. Fiscal year 2025, as reported to the SEC.

Total compensation

$1.3M

$1,296,528 for fiscal 2025: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-04-17SEC accession number 0001193125-26-161512

In context

The median chief executive among 61 Pharmaceuticals & Biotechnology companies with $100M – $500M in revenue was paid $3.2M. The middle half ranged from $1.9M to $4.2M.

Sravan K. Emany's total is below that median.

See how your pay compares to Beam Therapeutics Inc.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: Beam Therapeutics Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2025. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.